On July 3, 2018, BioVie Inc. (OTCQB: BIVI), an iBIO PROPEL company developing innovative drug therapies for liver disease, executed an agreement with Acuitas Group Holdings, LLC (“Acuitas”) and certain other investors to purchase $3.2 million of the Company’s Series A Preferred Stock
The iBIO Institute Honors Life Sciences Educators, Innovators and Entrepreneurs at the 12th Annual iCON Awards
This evening, the iBIO Institute hosted the twelfth annual iCON awards last night at The Chicago Botanic Garden.
